Century Therapeutics Price to Book Ratio

Century Therapeutics (IPSC) currently reports a P/B ratio of 1.76. That is below the Healthcare sector average of 6.23. Use the charts on this page to explore Century Therapeutics's P/B ratio history and peer comparisons.

Century Therapeutics's P/B ratio of 1.76 is lower than the Healthcare sector average of 6.23. That is roughly 71.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/B ratio is a valuation multiple that relates Century Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 1.76, IPSC can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/B ratio of 1.76, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 6.23. From there, open related valuation or income-statement pages for Century Therapeutics, and consider following IPSC for alerts when major investors trade the stock.

Century Therapeutics is classified in the Healthcare sector. On P/B ratio, it currently shows 1.76 versus a sector average near 6.23. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPSC with unrelated industries.